DAYBREAK - Racial Disparity in Lung Cancer Treatment Must Be Overcome

This page is in an archival section of the web site; the information may be outdated.
For current content, please visit UCSF Today at http://www.ucsf.edu/today/

Today's
Headlines

This Week's
News

1st appeared 14 October 1999

Racial Disparity in Lung Cancer Treatment Must Be Overcome

Preventing lung cancer is easier than curing it, and any barriers that inhibit blacks from full access to care must be removed, emphasize two doctors at UCSF.

In an editorial in the current issue (October 14) of The New England Journal of Medicine, UCSF co-authors Talmadge E. King, Jr. and Paul Brunetta analyze study findings that suggest racial attitudes may contribute to the fact that blacks have a higher death rate from lung cancer than whites.

The co-authors note that some of the disparity in lung cancer survival among blacks and among whites can be explained through smoking prevalence, how the body metabolizes and excretes carcinogenic and mutagenic agents in tobacco smoke, socioeconomic status, and access to health care. But these factors account for only some of the inequities in morbidity and mortality in the two population groups, emphasize King and Brunetta, both of whom are experts in pulmonary disorders.

In their editorial, the co-authors discuss three key areas that could impact survival rates among blacks and whites:

Racial differences between physicians and patients: This difference is often a barrier to optimal patient-physician communication and partnership. Black patients are more likely than white patients to feel excluded from decisions affecting their health, and this may be an important contributor to miscommunication. Both black patients and white patients appear more likely to feel involved with their own care when their doctors are of the same race, but blacks are far less likely to have a black physician as part of their care team, they write.

Lack of screening tests: There is no regular screening test for lung cancer to enhance early detection and reduce mortality, and many blacks do not undergo preventive screening for cancer because their physicians do not recommend the tests. Should effective lung-cancer screening become available, "we will need large-scale public health initiatives to make black patients, and their physicians, aware of its importance," they write.

Clinical trials: Most of the knowledge about the best lung cancer treatments has and will come from clinical trials. Many blacks are reluctant to enroll in these protocols due to the aftermath of several shameful episodes in US history, such as the Tuskegee study of untreated syphilis in a group of black men in rural Alabama from 1932-72. Thus, physicians making recommendations to patients about research trials should be sensitive to these issues. In addition, they state, agencies that fund cancer research should devote more resources to maintaining adequate representation of racial and ethnic minority groups in clinical studies and to increasing the number of minorities.

In summary, the UCSF co-authors write, "If the poor statistics on survival for the leading cause of cancer deaths in the United States are partially due to racial discrimination that results in inadequate emphasis on prevention or insufficiently aggressive care for blacks, then the medical establishment begins to share a portion of the tobacco industry’s culpability for the dismal outcome of patients with this disease."

Links:

Full UCSF press release

The New England Journal of Medicine

UCSF Cancer Center